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Shiga toxin producing Escherichia coli (STEC) are a major cause of food-borne illness
worldwide. However, a consensus regarding the role Shiga toxins play in the onset of
diarrhea and hemorrhagic colitis (HC) is lacking. One of the obstacles to understanding
the role of Shiga toxins to STEC-mediated intestinal pathology is a deficit in small animal
models that perfectly mimic human disease. Infant rabbits have been previously used
to study STEC and/or Shiga toxin-mediated intestinal inflammation and diarrhea. We
demonstrate using infant rabbits that Shiga toxin-mediated intestinal damage requires
A-subunit activity, and like the human colon, that of the infant rabbit expresses the
Shiga toxin receptor Gb3. We also demonstrate that Shiga toxin treatment of the infant
rabbit results in apoptosis and activation of p38 within colonic tissues. Finally we
demonstrate that the infant rabbit model may be used to test candidate therapeutics
against Shiga toxin-mediated intestinal damage. While the p38 inhibitor SB203580 and
the ZAK inhibitor DHP-2 were ineffective at preventing Shiga toxin-mediated damage to
the colon, pretreatment of infant rabbits with the drug imatinib resulted in a decrease of
Shiga toxin-mediated heterophil infiltration of the colon. Therefore, we propose that this
model may be useful in elucidating mechanisms by which Shiga toxins could contribute to
intestinal damage in the human.
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INTRODUCTION
Shiga toxin-producing Escherichia coli (STEC) are a heterogenous
group of E. coli strains responsible for food- and water-borne ill-
ness worldwide. Depending on the strain, approximately 5–22%
of infected individuals will suffer severe illnesses that can result
in permanent disability or death (Paton et al., 1998; Kulasekara
et al., 2009; Frank et al., 2011). Severe illnesses attributed to
STEC-associated sequelae include hemorrhagic colitis (HC) and
the hemolytic uremic syndrome (HUS), the predominant cause
of renal failure in US children (Siegler, 2003). Other than vol-
ume expansion during the diarrheal phase, no approved specific
preventative treatments exist for STEC-associated HUS.
Shiga toxins (Stxs) are the key virulence factors responsi-
ble for promoting severe disease during STEC infection. Stxs
are AB5 toxins consisting of a single A-subunit non-covalently
bound to 5 B-subunits. The B-subunits are necessary for bind-
ing of the toxin to the surface of the host cells via interac-
tion with neutral glycolipids with the glycosphingolipid receptor
globotriaosylceramide (Gb3) being themajor receptor (Lingwood
et al., 2010). Once bound, the toxin undergoes receptor-mediated
endocytosis and is transported retrograde through the early
endosome, the Golgi apparatus, and to the endoplasmic retic-
ulum (ER). Somewhere between the early endosome and the
trans-Golgi network, the enzymatically active portion of the
A-subunit is proteolytically cleaved possibly by furin into an
A1 fragment which remains bound to the A2 fragment and
non-covalently associated B-subunits via an intramolecular disul-
fide bond (Garred et al., 1995a,b; Tam and Lingwood, 2007).
Eventually the disulfide bond is reduced, possibly in the ER
(Spooner and Lord, 2012), and the enzymatically active A1 frag-
ment is translocated to the cytoplasm, where its N-glycosidase
activity results in the depurination of a single adenine residue
located in the alpha-sarcin/ricin loop of the 28S ribosomal RNA
(Endo and Tsurugi, 1987; Endo et al., 1987, 1988). This depuri-
nation event results in the cessation of protein synthesis in the
translational elongation phase and activates a proinflammatory
signaling cascade referred to as the ribotoxic stress response (RSR)
(Iordanov et al., 1997).
The RSR is defined as the activation of MAPKinases by cer-
tain protein synthesis inhibitors including Shiga toxins, ricin,
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anisomycin, doxorubicin, and the trichothecene mycotoxins
(Iordanov et al., 1997, 1998; Shifrin and Anderson, 1999; Smith
et al., 2003; Zhou et al., 2003; Sauter et al., 2010). The RSR has
been shown to result in a paradoxical up-regulation of several
cytokines despite a decrease in global protein synthesis (Thorpe
et al., 1999b, 2001; Foster and Tesh, 2002; Cherla et al., 2006;
Gonzalez et al., 2006). Finally, activation of pro-apoptotic signal-
ing has also been shown to occur following the activation of the
RSR (Smith et al., 2003). However, the role of the RSR in Shiga
toxin-mediated pathology in vivo has not been determined.
As STEC strains are generally non-invasive, it is believed
that HUS results from the systemic uptake of Shiga toxins and
possibly other virulence factors (e.g., LPS) from the intestinal
lumen. Both transcellular and a paracellular route have been
noted as pathways by which Stx may enter the systemic circu-
lation from the intestinal lumen (Acheson et al., 1996; Hurley
et al., 2001; Malyukova et al., 2009). Data suggests that Stx can
enter and cross the intestinal epithelium via receptor independent
macropinocytosis, (Malyukova et al., 2009; Lukyanenko et al.,
2011). This transcellular transcytosis may represent the major
pathway, at least during the early stages of infection, by which
Stx enters the systemic circulation. Alternatively, Stx and/or other
STEC virulence factors may contribute to Stx systemic uptake
by increasing the overall state of intestinal inflammation. It has
been demonstrated in vitro that a decrease in epithelial bar-
rier function to Stx correlates with neutrophil transmigration
across polarized intestinal epithelial cells (Hurley et al., 2001),
suggesting that Stxs could cross the intestinal epithelium via a
paracellular route that is promoted by inflammation. Therefore,
the inflammation and damage to the intestine that occurs dur-
ing HC (Griffin et al., 1990) may compromise intestinal barrier
function and promote systemic disease (i.e., HUS). However,
the exact mechanism(s) by which Shiga toxins themselves con-
tribute to this compromise of gut barrier function remains
unclear.
In order to intoxicate and thereby induce an inflammatory
response, Stx must bind and enter cells via receptor-mediated
endocytotic pathways (Jacewicz et al., 1994; Khine et al., 2004;
Zumbrun et al., 2010). Gb3 is the best characterized cell sur-
face receptor through which Stx binds and enters cells (Waddell
et al., 1988, 1990; Sandvig et al., 1991; Lingwood et al., 1998).
While it has been shown in rabbits that Gb3 is maturationally
regulated in the small bowel (Mobassaleh et al., 1994), noth-
ing is known concerning Gb3 levels in the rabbit colon. In the
present study, we use an infant rabbit oral intoxication model
(Ritchie et al., 2003) with purified Stx2 and an enzymatically inac-
tive Stx2AY177S,E167QB to investigate the role of Stx2 subunits in
toxin-induced colonic inflammation.We assess Gb3 expression in
the infant rabbit colon and demonstrated Stx2-mediated activa-
tion of the MAPK p38 in intestinal tissue. Finally, we investigate
whether treatment with inhibitors of the RSR may prevent or
lessen Stx2-induced intestinal inflammation.
MATERIALS AND METHODS
ANTIBODIES, INHIBITORS, AND OTHER REAGENTS
Antibodies to phospho-p38 (cat# sc-7973) were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The
DNA plasmid expressing Stx2AY177S,E167QB (pNR100) was
provided to us by Dr. Tom Obrig of the University of Maryland
(Baltimore, MD) and its construction was previously described
by Wen et al. (2006). Both Stx2 and Stx2AY77S,E167QB were
purified by Dr. Anne Kane of the Phoenix Lab at Tufts
Medical Center (Boston, MA) using previously described
techniques (Donohue-Rolfe et al., 1989). The ZAK specific
inhibitor 7-[3-fluoro-4-aminophenyl-(4-(2-pyridin-2-yl-5,
6-dihydro-4Hpyrrolo[1,2-b]pyrazol-3-yl))]-quinoline DHP-2
was synthesized by Albany Molecular Research (Albany, NY).
Imatinib mesylate (Novartis, Cambridge, MA) was purchased
from the Tufts Medical Center Pharmacy. The p38 inhibitor
SB203580 was purchased from LC Laboratories (Woburn, MA).
CELL CULTURE
Tissue culture media and reagents were obtained from Gibco
BRL-Life Technologies (Grand Island, NY). HCT-8 cells were
maintained at 37◦C in an atmosphere of 5% CO2 in RPMI
1640 medium supplemented with 10mM HEPES, 1mM sodium
pyruvate, 10% heat-inactivated FCS, 50 IU/ml of penicillin, and
50μg/ml of streptomycin and used at 90–100% confluence.
ANIMAL PROTOCOLS
All procedures involving live animals were pre-approved by our
institutional animal care and use committee. Two-day old New
Zealand White rabbits were obtained with doe from Millbrook
Labs (Amherst, MA). Each litter was housed as a group and
nursed by the mother. Three day old rabbits were given Stx2,
Stx2AY77S,E167QB, or heat-inactivated Stx2 intragastrically in
doses of 1.0mg/kg of rabbit weight daily for 2 consecutive days,
followed by euthanasia and necropsy. The first day of toxin
administration was designated “day 0”. For studies involving
inhibitors, rabbits were given either vehicle, 20mg/kg SB203580
every 12 h by intraperitoneal injection, 30mg/kg DHP-2 every
24 h by oral gavage, or 1.5mg/kg imatinib every 12 h by oral
gavage, beginning on day 2 of life (day –1), then re-dosed
every 12 h (vehicle, SB203580 or imatinib) or every 24 h (vehi-
cle or DHP-2), until euthanasia and necropsy. Infant rabbits
were weighed daily and monitored twice daily for signs of ill-
ness. Diarrhea was scored as follows: none= no diarrhea (normal
pellets are dark green, hard, and formed); mild = diarrhea con-
sisting of light heel staining; or moderate = diarrhea consisting
of staining of the perineum, hind legs, and heels with occasional
unformed stool adherent. All rabbits were euthanized by isoflu-
rane inhalation until unresponsive to painful stimulus, followed
by intracardiac injection of euthasol (Virbac Animal Health Inc.,
Fort Worth, TX).
At necropsy, the intestinal tract from the anus to the mid-
colon was removed, and samples were obtained for lipid extrac-
tion, histology, and/or immunohistochemistry. To eliminate any
litter-specific effects, all experimental conditions (treatments and
controls) were represented, in each litter treated. Thus small lit-
ters, large litters (>10 pups), or litters inwhich there were extreme
variations in pup size were not used. In order to achieve suf-
ficient power, 5 different litters consisting of 32 animals were
used for the study comparing Stx2 with the enzymatically inactive
Stx2AY177S,E167QB, 4 litters consisting of 31 animals were used for
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the SB203580 study, 3 litters consisting of 20 animals were used
for the DHP-2 study, and 8 litters consisting of 49 animals were
used for the imatinib study.
HISTOLOGY
Except for the tissue used for Gb3 analysis (detailed further
below), all other distal colon tissue obtained at necropsy was
immediately fixed in 10% buffered formalin, then paraffin-
embedded. Sections 5μm thick were obtained and mounted
on glass slides. Slides for histological analysis of inflammation
were stained with hematoxylin and eosin (H&E). The slides
were then blindly scored by a veterinary pathologist on four
criteria including heterophil, epithelial defects, edema, and con-
gestion/hemorrhage, or on 5 criteria that included heterophils,
epithelial defects, congestion/edema/hemorrhage, mononuclear
cells, and atrophy. A scale from 0 to 4 was used with 0 being the
least severe or lowest, and 4 being the most severe or highest.
LIPID EXTRACTION AND THIN LAYER CHROMATOGRAPHY
Tissues from the large intestine (distal and mid-colon), cecum,
and ileum were collected and processed to isolate neutral lipids
according to previously described methods (Nutikka et al., 2003;
Kolling et al., 2008). Saponified neutral lipid fractions were sep-
arated by thin layer chromatography and Gb3 detected using the
toxin overlay method (Nutikka et al., 2003). Lipid standards were
purchased from Matreya LLC (Pleasant Gap, PA). Toxin overlays
were conducted using Stx1B and an anti-polyclonal Stx1B anti-
body (gift from Dr. C. A. Lingwood, Hospital for Sick Children,
Toronto, ON).
IMMUNOHISTOCHEMISTRY FOR Gb3
Anti-Gb3 immunohistochemistry was performed on paraffin
embedded sections of rabbit colon using the method of Kolling
with modifications (Kolling et al., 2008). Briefly, tissues were fixed
with 4% paraformaldehyde (PFA) in phosphate buffered saline
(PBS) for 24 h at room temperature and washed with PBS. Tissues
were dehydrated using an acetone gradient; 25% for 10min ×
2, 75% for 10min × 2, 95% for 20min × 2, and 100% for
20min × 2 and then immersed in xylenes for 5min × 2 prior
to paraffin embedding. The paraffinized blocks were sectioned
to 3μm. Following antigen retrieval using a microwave oven, the
Vectastain ELITE ABC (VECTOR laboratories, Burlingame, CA)
reagent protocol was followed with the exception that endoge-
nous IgM was blocked with goat anti-rat IgM (H&L)F(ab′)2
using a 1:50 dilution (American Qualex, San Clemente, CA).
The primary antibodies used were CD77/Gb3 monoclonal rat
IgM antibody (clone 38.13, Immunotech/Beckman Coulter,
Brea, CA) and as a control, an isotype matched rat IgM
from Chemicon/Millipore (Billerica, MA). The secondary anti-
body used was anti-rat IgM-biotin conjugate from American
Qualex.
IMMUNOHISTOCHEMISTRY FOR PHOSPHO-p38
Immunostaining was performed using formalin-fixed paraffin-
embedded 5μm thick intestinal sections. Sections were
deparaffinized, hydrated, and subsequently subjected to
microwave antigen retrieval using a target retrieval solution
(Dako, Carpinteria, CA) at pH 10.00. Endogenous peroxidase
was blocked with 3% H2O2/H2O, and a serum-free protein block
(Dako) was used to prevent non-specific protein binding. Tissue
sections were incubated overnight with antibodies against acti-
vated (i.e., phosphophorylated) p38 (1:100; Santa Cruz Biotech,
CA) at 4◦C, followed by biotinylated anti-mouse secondary
antibody and a peroxidase-labeled streptavidin-biotin (Dako).
The 3-amino-9-ethylcarbazole (AEC) substrate-chromogen
(Dako) detection method for immunostaining was used and sec-
tions were counterstained with Mayer’s hematoxylin. Specificity
of staining was confirmed by omitting the primary antibody
(negative controls).
TERMINAL DEOXYNUCLEOTIDYLTRANSFERASEBIOTIN-dUTP NICK
AND LABELING (TUNEL) STAINING
To detect DNA fragmentation due to apoptosis, paraffin sections
were stained using the ApopTagPlus Peroxidase In Situ apoptosis
detection kit (Millipore, MA). In short, sections were deparaf-
finized and treated with proteinase K for antigen retrieval. After
endogenous peroxidase blocking, digoxigenin (DIG)-conjugated
nucleotides were incorporated to 3′-OH nicks of DNA using
terminal deoxynucleotidyltransferase (TdT). The labeled DNA
sites were visualized using peroxidase labeled anti-DIG and
3,3′-diaminobenzidine (DAB). DAB positive brown nuclei were
counted and normalized to total viewing area.
STATISTICAL ANALYSIS
Histology scores are ordinal non-parametric data, and were ana-
lyzed either by One-Way ANOVA analysis for the data presented
in Figure 2, or by the Mann–Whitney U-test (Figures 4 and 9)
using Prism software (GraphPad, San Diego, CA).
RESULTS
HETEROPHIL INFILTRATION AND EPITHELIAL DEFECTS ARE
DEPENDENT ON Stx2 CATALYTIC ACTIVITY
Members of our group have previously reported that following
oral administration of 100μg/kg of Stx2, given as a repeated dose
on day 0 and day 1, rabbits developed diarrhea by day 2 compared
with animals dosed with heat-inactivated Stx2 (HI) as a control
treatment (Ritchie et al., 2003). Furthermore, when compared
to animals given HI, rabbits given purified Stx2 had significantly
more heterophils in the distal colonic mucosa and more epithelial
defects consisting of crypt abscesses, crypt ectasia, and distor-
tion and intraluminal plugging of degenerating heterophils and
epithelial cells.
The results from several studies have suggested that the Stx
B-subunit has the ability to promote innate immune signal-
ing, apoptosis, and/or thrombotic microangiopathy (Mangeney
et al., 1993; Nakagawa et al., 1999; Fischer et al., 2007; Huang
et al., 2010). To determine if Stx2-induced intestinal dam-
age was dependent on Stx2 A-subunit N-glycosidase activity,
we compared the effects of oral Stx2 treatment with that of
Stx2AY177S,E167QB (Mut), a Stx2 mutant toxin with active site
mutations in the Stx2 A-subunit (Deresiewicz et al., 1992; Wen
et al., 2006). In each of 5 litters of infant rabbits, individ-
ual animals were intoxicated once a day with 100 ug/kg of HI,
Mut, or Stx2 for 2 days. Compared with rabbits intoxicated
with Stx2 (Figures 1 and 2), there was a statistically significant
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FIGURE 1 | H and E stained sections of infant rabbit colon following
treatment with (A) HI, (B) Mut, or (C) Stx2. Tissue from Stx2-treated
rabbits show increased edema, epithelial defects (Epith def), and heterophil
infiltration.
(P < 0.05) decrease in heterophils, epithelial defects, edema,
and congestion/hemorrhage observed in animals given Mut.
These parameters were not significantly different (i.e., P > 0.05)
between HI- vs. Mut-treated animals in any of the four cate-
gories. In agreement with these data, TUNEL staining of colon
sections (Figures 3 and 4) from two of the 5 litters (n = 4 for each
treatment) demonstrate that Stx2-treated animals had increased
numbers of apoptotic cells compared with those treated with HI
and Mut. In addition, most of the TUNEL positive cells in the
Stx2-treated animals were found either apically near the brush
border or between the brush border and basal lamina with rel-
atively few being detected in the submucosa (data not shown).
Since the B-subunit is present in both Stx2 and Mut preps,
data suggests that in this model, Stx2-induced intestinal dam-
age and apoptosis is largely dependent on A-subunit catalytic
activity.
Gb3 IS DETECTABLE IN THE DISTAL COLONIC EPITHELIUM IN 5-DAY
OLD INFANT RABBITS AND IS AFFECTED BY Stx2 TREATMENT
Recent studies suggest that the human colonic epithelium
expresses Gb3 (Zumbrun et al., 2010). In rabbits Gb3 is matu-
rationally regulated in the small bowel (Mobassaleh et al., 1994),
which is why wide cell intestinal apoptosis is observed in adult
rabbits challenged with Stx in ileal loop models (Keenan et al.,
1986). In contrast, nothing is known about Gb3 levels in the rab-
bit colon. To determine if Gb3 is present in colonic tissue of 5-day
old rabbits, 1 cm tissue sections were subjected to lipid extraction
followed by thin-layer chromatography. Gb3 was detected in the
distal colon of animals challenged with HI or Mut, while Stx2-
treated animals appeared to have little or no Gb3 (Figures 5 and
6). Similarly, immunohistochemical staining of tissue sections
from infant rabbit colon revealed the presence of Gb3 (Figure 6),
which decreases following Stx treatment. Therefore, infant rabbit
colon expresses Gb3.
Stx2 INDUCES PHOSPHORYLATION OF p38 IN INFANT RABBIT COLON
In previous studies, we have shown that Stxs induce the RSR in the
human colonic epithelial cell line HCT-8 (Smith et al., 2003), and
that the resultant activation of the MAPKinases p38 and the Jun
N-terminal kinases (JNKs) are essential for induction of several
proinflammatory cytokines. We therefore investigated whether
p38 activation could be detected in the colon of Stx2-treated
animals (Figure 7). Although present in both samples, intestinal
levels of P-p38 are higher in Stx2-treated compared with Mut-
treated infant rabbits suggesting that p38 is indeed activated in
response to Stx2.
We have also shown that inhibition of p38 diminishes Stx2-
induced pro-inflammatory cytokine production in intestinal
epithelial cells (Thorpe et al., 1999a). To determine whether
inhibition of p38 activity in vivo results in decreased colonic
inflammation, we pre-treated infant rabbits by intraperitoneal
injection with the p38 inhibitor SB203580. Following intoxica-
tion with Stx2, no significant histopathological differences were
detected between SB203580-treated vs vehicle treated animals
(data not shown).
EFFECTS OF THE ZAK INHIBITOR DHP-2 ON Stx2-INDUCED COLONIC
INFLAMMATION
We next chose to target the MAPKinase pathway more proxi-
mally at the MAP3Kinase level. The MAP3Kinase ZAK has been
shown to induce the Stx-mediated RSR in vitro (Jandhyala et al.,
2008), and we have demonstrated that the ZAK specific inhibitor
DHP-2 (Wang et al., 2005) was effective at the inhibition of Stx2-
induced activation of p38 and JNKs in HCT-8 cells. Therefore, we
investigated whether DHP-2 could prevent Stx2-induced pathol-
ogy. Infant rabbits were treated with DHP-2 by oral gavage prior
to Stx2 intoxication. As with the SB203580 treatments (data not
shown), no significant difference in histopathology was detected
between vehicle and DHP-2 treated rabbits.
TREATMENTWITH THE TYROSINE KINASE AND ZAK INHIBITOR
IMATINIB REDUCES HETEROPHIL INFILTRATION IN RESPONSE TO Stx2
Ricin cleaves the same adenine from the α-sarcin/ricin loop
of the 28S rRNA as Stx and initiates a similar ribotoxic stress
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FIGURE 2 | Five litters composed of 32 animals were treated once a
day for 2 days with 100µg/kg of heat-inactivated Stx2 (HI) (n = 7),
Stx2AE167QY77SB (Mut) (n = 14), or Stx2 (n = 11). Blinded scoring was
performed for heterophil infiltration and epithelial defects. Similarly,
tissue was scored for edema and congestion/hemorrhage for tissue
samples from four of the five litters (HI, n = 6; Mut, n = 10;
Stx2 n = 8). ∗Significance (P -value < 0.05) was determined by one-way
ANOVA.
FIGURE 3 | Panels showing representative differences in TUNEL
positive cells (arrows) in the colon of heat-inactivated Stx2-, mutant-,
and wild type Stx2- treated animals.
response, resulting in increased pro-inflammatory gene expres-
sion (Iordanov et al., 1997; Smith et al., 2003). In 2010, Lindauer
et al. demonstrated that nilotinib and sorafenib could block
ricin mediated p38 and JNKs activation (Lindauer et al., 2010).
Nilotinib and sorafenib are drugs used to treat myelogenous
leukemia and renal cancer respectively by inhibiting the tyro-
sine kinase activities of the oncoprotein BCR-Abl (nilotinib) or of
vascular endothelial growth factor receptor and platelet-derived
growth factor receptor (sorafenib). However, studies have also
shown that these and other antineoplastic drugs, including the
BCR-Abl inhibitors dasatinib and imatinib, have affinity to and/or
can inhibit additional kinases including ZAK (Karaman et al.,
2008; Manley et al., 2010). Because these kinase inhibitors are
known to be pharmacologically active in vivo, have been well-
studied inmouse models, and are approved for use in humans, we
thought they might be good candidates for testing in our infant
rabbit model.
We tested the effects of imatinib and dasatinib on inhibi-
tion of Stx2-induced ribotoxic stress in vitro using HCT-8 cells.
Both imatinib and dasatinib when administered at 200μM had
a clear inhibitory effect on Stx2-induced p38 phosphorylation
(Figures 8A and C). However, only imatinib showed inhibition
of Stx2-induced JNKs phosphorylation (Figures 8A and B) while
dasatinib at 200μM appeared to promote JNKs phosphorylation
even in the absence of Stx2. Despite imatinib having a relatively
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FIGURE 4 | Tissue sections from HI, Mut, and Stx2-treated animals
(n = 4 for each from a single litter) were analyzed for apoptotic events
by TUNEL staining. For a given experiment, the number of apoptotic cells
were counted per unit area and then normalized against those of the
HI-treated animals. The normalized values are shown for each individual
animal along with the median (horizontial line). ∗Significance as determined
by the Mann–Whitney U-test P = 0.029.
FIGURE 5 | (A) Thin layer chromatography of extracted lipids from the distal
colon tissue of 2 HI, 4 Mut-, and 3 Stx2-treated infant rabbits. Gb3 was
detected using a Shiga toxin 1 B-subunit overlay method (Nutikka et al.,
2003). Standards of 0.8, 0.4, and 0.2μg Gb3 are shown on the far left of
the TLC plate. (B) TLC band density for each sample was determined using
ImageJ 1.38× software (Rasband, 1997–2007). (C) Mean density values
were plotted for each treatment group. Error bars represent the standard
deviation.
low affinity for ZAK, (Kd = 2.6μM) compared to dasatinib
(Kd = 45 nM), nilotinib (Kd = 8–10 nM), and sorafinib (Kd =
6.3 nM) (Karaman et al., 2008; Manley et al., 2010) we chose to
test imatinib in our rabbit model as it was readily available at
our hospital pharmacy in the form of a pharmaceutical-grade
tablet.
We elected to administer imatinib to infant rabbits using a
dose of 125mg/kg every 12 h by oral gavage. Of the 49 rab-
bits used for this study, 23 were treated with Stx2 (13 with
vehicle and 10 with imatinib), and 26 were treated with HI
(14 with vehicle and 12 with imatinib). All Stx2-treated ani-
mals developed diarrhea regardless of inhibitor or vehicle pre-
treatments. However, the imatinib-treated animals (Figure 9) had
statistically less heterophil infiltration into the intestinal mucosa
(P = 0.008) compared with those animals pre-treated with vehi-
cle, suggesting that the imatinib did confer some protective
effect. There was also a slightly lower mean score (non-significant
P = 0.06) for epithelial defects in the imatinib treated animals.
At the dose we used, there was no effect of imatinib adminis-
tration on basal inflammation observed in control (HI-treated)
animals.
DISCUSSION
One of the barriers to the development of therapeutics to treat
Shiga toxin-mediated illnesses has been the lack of good small-
animal models, in which oral challenge with STEC results in
diarrhea followed by hemolytic uremic syndrome with renal
and neurological pathology. Small-animal models for studying
STEC generally fail to consistently replicate all facets of STEC-
mediated disease (Proulx et al., 2001). For example, although
the infant rabbit has proven to be very useful for studying
intestinal colonization by STEC strains (Ritchie et al., 2003,
2011; Ritchie and Waldor, 2005; Ho et al., 2008; Vazquez-Juarez
et al., 2008), the animals do not develop thrombotic microan-
giopathy. Because STEC-mediated disease clearly starts in the
intestine, and the role of Stxs in intestinal disease is poorly under-
stood, the infant rabbit model may be a useful one in which
to study how Stxs can contribute to intestinal damage during
STEC infection. The widely accepted assertion that the Stx recep-
tor Gb3 is absent in the human intestinal epithelium, confines
Stx-mediated effects to the Gb3-positive intestinal microvascula-
ture, myofibroblasts, neuroendocrine cells, and Paneth cells and
has resulted in downplaying the role of Stxs in intestinal pathol-
ogy (Schuller et al., 2004, 2007; Schuller, 2011). However, by
demonstrating that Stxs do bind to human colonic epithelium,
and that Gb3 synthase, the enzyme that synthesizes Gb3 from lac-
tose ceramide, is expressed in these cells, a study by Zumbrun
et al., 2010 was able to conclude that Gb3 is expressed in the
human intestinal epithelium albeit at low levels (Zumbrun et al.,
2010). Therefore Stxs may play a more significant role in pro-
moting intestinal damage during STEC infection than some have
perceived.
A large obstacle to understanding the role of Stxs in STEC-
mediated intestinal disease is that STEC strains differ with respect
to the arsenal of virulence factors they express, thereby making it
difficult for researchers to reach a consensus as to which virulence
factors are necessary or most important for promoting intestinal
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FIGURE 6 | (A–C), (D–F), (G–I) and (J–L) are colon sections from naïve,
Stx2, heat-inactivated Stx2 and Stx2 mutant treated rabbits, respectively.
(A, D, G and J) are sections stained with anti-Gb3 antibody. Strong signal
in A (luminal layer) and less intense stain in G and J can be recognized,
whereas no signal is detected in D (Stx2 treated). Arrowheads show
examples of Gb3 positive spots. In (B, E, H and K), isotype matched rat
IgM was used in the place of anti-Gb3 antibody to serve as a negative
control. (C, F, I and L) are primary antibody omitted, buffer control
(negative control). All controls shown are negative. A scale bar in (A)
indicates 50mm.
pathology and (presumably) subsequent systemic uptake of Stxs.
Several virulence factors, including flagellins and factors associ-
ated with the locus of enterocyte effacement (LEE) have been
implicated as some of the more important contributors to
intestinal pathology during STEC colonization (Ritchie et al.,
2003; Rogers et al., 2003; Miyamoto et al., 2006). Therefore,
in order to fully evaluate the role of Stxs in intestinal disease,
the use of models in which toxins can be effectively adminis-
tered in the absence of other known virulence determinants is
important.
In this study, we use the infant rabbit as a model to investi-
gate specifically Stx-induced intestinal pathology. We show that
Stx2-induced colonic inflammation in infant rabbits is associated
with A-subunit activity, cannot be induced by holotoxin in the
absence of N-glycosidase activity, and is associated with activa-
tion of the SAPKinase p38. These findings are all consistent with
the hypothesis that Stx2 induces the RSR in this model. Unlike
the small bowel of rabbits in which Gb3 is maturationally regu-
lated and toxin binding of Gb3 in jejunal microvillus membranes
can only be detected after day 16 of life (Mobassaleh et al., 1988),
our studies demonstrate that Gb3 is present in the colon by day
5. While it has been suggested that for cytotoxicity, endocyto-
sis, and trafficking through the Golgi apparatus, Stx requires
cell surface Gb3 localized in lipid rafts (Falguieres et al., 2001;
Utskarpen et al., 2010), other studies have concluded that Stxs are
able to enter cells independent of Gb3 (Malyukova et al., 2009).
However, the extent of cellular damage caused by Stx following
Gb3-independent entry was not determined in those studies. It
should be noted that Gb3-independent macropinocytosis of Stx
as proposed by Malyokova et al., may still contribute to intesti-
nal inflammation by exposing Gb3-positive intestinal endothelial,
myofibroblast, and neuroendocrine cells to Stx. Also, Stx2 but
not Stx1 treatment of human intestinal biopsy cultures revealed
epithelial cytotoxicity with pronounced cell extrusion from the
crypt rims and crypt centers (Schuller et al., 2004). Interestingly,
immunofluorescent staining of this tissue for Stx2 revealed strong
staining of the lamina propria in proximity to pericryptal myofi-
broblasts, scattered stromal cells, and the epithelium. Together
these data support a role for Stx2 in promoting damage to the
human intestine during STEC infection.
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FIGURE 7 | Immunohistochemical staining of phosphorylated-p38 in
colon sections from (A) Mut- or (B) Stx2-treated infant rabbits. Dark
brown staining is indicative of the presence of phosphorylated p38.
Our observations that Gb3 is not detectable following Stx2
treatment supports the hypothesis that Stx2 is entering cells via
this receptor and that intoxicated cells are either dying or are
prevented from regenerating new Gb3. That the same magnitude
of decrease does not occur in either HI- or Mut-treated animals
suggests the enzymatic activity of the wild type Stx2 is promot-
ing the loss of detectable Gb3 in these tissues. At the same time,
the decrease in epithelial cell Gb3 in both HI-treated and Mut-
treated animals compared to untreated animals is interesting, and
may be worthy of further study. It is possible that the Stx2 cat-
alytic mutant is bound to and taken up by Gb3-positive cells
resulting in a decrease of detectable Gb3 at the surface of the
cells, and that Gb3 is then replaced or regenerated as intoxication
does not occur. It is also possible that similar events occur with
our heat-inactivated preparation of Stx2 because it may retain
B-subunit activity, as holotoxin, in general, is very heat stable
(unpublished observations, Jandhyala et al.). Indeed, Fischer et al.
have demonstrated in vitro that treatment of A498 cells with StxB
but not holotoxin results in the release of free ceramide, suggest-
ing that interaction of Gb3 with StxB may promote hydrolysis of
the glycosphingolipid (Fischer et al., 2007).
Based on these data, we suggest that the infant rabbit is a use-
ful model to study the contribution of Stx2 to various aspects
of disease pathogenesis during the diarrheal phase of human ill-
ness. It may also be a useful model in which to study the exact
mechanism(s) by which Shiga toxins breach the epithelial bar-
rier in order to be taken up from the intestinal compartment
FIGURE 8 | Confluent HCT-8 cells were pretreated for 1 h with DMSO
(vehicle), 200µM imatinib, or 200µM dasatinib. Cells were then left
untreated or treated with 5μg/ml of Stx2 for 4 h. 150μg of protein from
each whole cell lysate was loaded in each lane. (A) Western blots were
performed for phospho-JNKs, phospho-p38, and total ERKs (loading
controls). Graphical representation of normalized band intensities are
shown for phospho-JNKs (B) and phospho-p38 (C).
into the systemic circulation. However, one obvious limita-
tion to our study is that we did not assess our animals for
the presence or absence of an alternate Stx receptor such as
globotetraosylceramide (Gb4), nor did we specifically evaluate
the role for Gb3 engagement by Stx2 on the host inflammatory
response or apoptosis. These are areas that may be of interest for
future studies.
Our attempts to use the infant rabbit model to test potential
therapeutics directed at inhibiting the Stx-mediated MAPKinase
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FIGURE 9 | Animals were treated with 125mg/kg imatinib 2 times
daily beginning 12h prior to HI or Stx2 dosing. The data represents
blinded scoring for heterophils and epithelial defects. ∗Significant
P -value = 0.0068; NS (not significant) P -value = 0.064. HI-vehicle
n = 14, HI-imatinib n = 12, Stx2-vehicle n = 13, and Stx2-imatinib
n = 10.
response had mixed results. There are several important inherent
difficulties in studying potential therapeutics in this specific
model that are worthy ofmention. First, little or nothing is known
about appropriate dosing of the candidate therapeutics in the
infant rabbit. When possible, we used doses and routes of admin-
istration of therapeutic candidates that had been successful in
other studies, and/or estimated dosing intervals based on the
assumption that infant rabbit metabolism would be similar to the
metabolism of adult mice. Infant rabbits are slightly larger than
adult mice, usually between 50 and 100 g on day 0, and they grow
rapidly during the 48 h of the study. However, it is purely specu-
lative as to how this observation may reflect the metabolism of a
given compound. Second, infant rabbits typically feed once daily,
but may feed more often, thus their stomach contents can vary
greatly at different times of the day. Also, not all animals in a litter
may feed equally well. Therefore, absorption of orally adminis-
tered compounds may differ between individuals. Finally, enteric
flora is being established in the first week of life, andmay therefore
be highly variable between litters and even within litters, which
may certainly affect immunologic responses in the intestine.
Pre-treating the rabbits with the p38 specific inhibitor
SB203580 resulted in no observed effect compared with vehicle
treated controls. We chose a dose that was comparable to that
used in murine models of arthritis and endotoxin shock (Badger
et al., 1996), but it may have been insufficient for our model.
Alternatively, blocking the other MAPKinase pathways down-
stream of ZAK such as JNKs and the extracellular receptor kinases
(ERKs), may be necessary in order to have a significant effect on
colonic inflammation, as the power of this study was only strong
enough to detect a difference greater than 1.00–1.5 scoring units.
Similarly, negative results were obtained using the ZAK inhibitor
DHP-2. It is possible that the lack of positive results are due to
sub-optimal dosing as no data has been published with regard
to the pharmacodynamics of this compound. The single pub-
lished use of this compound only described the treatment of mice
with DHP-2 by oral gavage 1 h prior sacrificing and dissecting the
animals (Wang et al., 2005).
Previous studies of EHEC and Stx using the infant rabbit
model demonstrated that Stx contributes to EHEC-associated
intestinal pathology by increasing heterophil infiltration (Ritchie
et al., 2003). Interestingly, pre-treatment with imatinib which has
been shown to have affinity for ZAK, seemed to have a modest,
but statistically significant decrease of Stx2-induced heterophil
infiltration. This is of particular note since it has been proposed
that infiltration of polymorphonuclear leukocytes (PMNs) may
promote systemic uptake of Stxs (Hurley et al., 2001). Indeed,
treatment of the intestinal cell line HCT-8 results in the induction
of the potent neutrophil chemo-attractant interleukin-8 (IL-8)
(Thorpe et al., 1999b), and there is a correlation between num-
bers of PMNs and increased IL-8 in both patients with HUS
and rabbits treated with Stxs (Fitzpatrick et al., 1992; Garcia
et al., 2008). Our finding that imatinib can block Stx2-induced
RSR events in intestinal epithelial cells in vitro, and decreases
heterophil infiltration in vivo, supports our hypothesis that Stx2-
induced ZAK activation is an upstream event contributing to the
Stx2-induced colonic inflammation observed in vivo. However,
future experiments aimed at evaluating MAPKinase activation
and downstream gene activation will be needed to confirm that
these observations are due to ZAK inhibition versus the inhibi-
tion of one or more other kinases. Also, future efforts to evaluate
the therapeutic potential of this class of agents will focus on other
drugs in this family, such as nilotinib, which has a much higher
affinity for ZAK (∼8–10 nM) than imatinib (2.6μM) (Karaman
et al., 2008; Manley et al., 2010) and has been shown in vitro to
block the RSR (Sauter et al., 2010). We have also recently devel-
oped a zak knockout murine line with a targeted deletion that will
be useful to further assess the role of ZAK activation in ribotoxic
stressor-induced inflammatory events in vivo.
In conclusion, we have demonstrated that Stx2A-subunit
activity is necessary for intestinal pathology, including apopto-
sis, in the colon of infant rabbits. We have also demonstrated
that a cell surface receptor for Stx, Gb3, is present in the infant
rabbit colon and provided data suggesting that Stx2 engages
these Gb3-positive cells. Finally, we have provided for the first
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time, in vivo data showing that a compound with affinity
for ZAK, may lessen Stx2-induced intestinal damage. Together
these data support the infant rabbit model as a reasonable
small-animal model for studying Stx-mediated intestinal disease
and evaluating candidate therapeutics for treating Stx-mediated
intestinal inflammation.
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